ArticleThe Journal of clinical investigation2020
Melanocortin-4 receptor antagonist TCMCB07 ameliorates cancer- and chronic kidney disease-associated cachexia.
Article in The Journal of clinical investigation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 51 citations in OpenAlex.
- Effect of preoperative immunonutrition on postoperative short-term clinical outcomes in patients with gastric cancer cachexia: a prospective randomized controlled trial.World journal of surgical oncology · 2024Trial
- Review
- The causes of cachexia: key signals and the brain.Nature reviews. Endocrinology · 2026Review
- Rationale of renewed efforts in developing MC4R modulators to treat metabolic disorders.Acta pharmaceutica Sinica. B · 2026Review
- Dual activation of MC3R and MC4R drives weight loss and reduces food intake in male primates with obesity.Nature communications · 2026Article
- Feeding Behaviour in the KPC Model of Pancreatic Cancer-Associated Cachexia: Alteration of Spontaneous and Evoked Feeding Behaviours.Journal of cachexia, sarcopenia and muscle · 2026Article
- Cancer cachexia: molecular basis and therapeutic advances.Signal transduction and targeted therapy · 2026Review
- Dependence of energy balance and hypothalamic neuropeptide gene expression on initial tumor load in mice.Frontiers in oncology · 2026Article
- Mechanisms of postoperative anorexia in surgical patients: a narrative review.Frontiers in neuroscience · 2026Review
- Systematic Exploration of Molecular Mechanisms and Natural Herbal Therapeutic Strategies for Cancer Cachexia.Cancers · 2025Review
- Cachexia and Wasting in Chronic Illness: Regulatory and Clinical Trial Update.Journal of cachexia, sarcopenia and muscle · 2025Article
- Role of Peptides in Skeletal Muscle Wasting: A Scoping Review.Journal of cachexia, sarcopenia and muscle · 2025Article
- Cancer-Associated Cachexia: Bridging Clinical Findings with Mechanistic Insights in Human Studies.Cancer discovery · 2025Review
- Weight loss in patients on osimertinib for metastatic EGFR-mutant non-small cell lung cancer.The oncologist · 2025Article
- Blood-Brain Barrier-Penetrating Nanocarriers Enable Microglial-Specific Drug Delivery in Hypothalamic Neuroinflammation.Advanced healthcare materials · 2025Article
- A neuroimmune circuit mediates cancer cachexia-associated apathy.Science (New York, N.Y.) · 2025Article
- Combating chronic kidney disease-associated cachexia: A literature review of recent therapeutic approaches.BMC nephrology · 2025Review
- Leptin signalling altered in infantile nephropathic cystinosis-related bone disorder.Journal of cachexia, sarcopenia and muscle · 2024Article
- Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss in rats.The Journal of clinical investigation · 2024Article
- Defining and Addressing Research Priorities in Cancer Cachexia through Transdisciplinary Collaboration.Cancers · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 3 countries.
Funding
Abstract
Cachexia, a devastating wasting syndrome characterized by severe weight loss with specific losses of muscle and adipose tissue, is driven by reduced food intake, increased energy expenditure, excess catabolism, and inflammation. Cachexia is associated with poor prognosis and high mortality and frequently occurs in patients with cancer, chronic kidney disease, infection, and many other illnesses. There is no effective treatment for this condition. Hypothalamic melanocortins have a potent and long-lasting inhibitory effect on feeding and anabolism, and pathophysiological processes increase melanocortin signaling tone, leading to anorexia, metabolic changes, and eventual cachexia. We used 3 rat models of anorexia and cachexia (LPS, methylcholanthrene sarcoma, and 5/6 subtotal nephrectomy) to evaluate efficacy of TCMCB07, a synthetic antagonist of the melanocortin-4 receptor. Our data show that peripheral treatment using TCMCB07 with intraperitoneal, subcutaneous, and oral administration increased food intake and body weight and preserved fat mass and lean mass during cachexia and LPS-induced anorexia. Furthermore, administration of TCMCB07 diminished hypothalamic inflammatory gene expression in cancer cachexia. These results suggest that peripheral TCMCB07 treatment effectively inhibits central melanocortin signaling and therefore stimulates appetite and enhances anabolism, indicating that TCMCB07 is a promising drug candidate for treating cachexia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.